These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 12891226

  • 1. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJ.
    Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
    Verschraagen M, Boven E, Zegers I, Hausheer FH, Van der Vijgh WJ.
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
    Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G.
    Br J Cancer; 2005 May 09; 92(9):1636-43. PubMed ID: 15841080
    [Abstract] [Full Text] [Related]

  • 4. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
    Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F.
    Cancer Chemother Pharmacol; 2003 May 09; 51(5):376-84. PubMed ID: 12682786
    [Abstract] [Full Text] [Related]

  • 5. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
    Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ.
    Biochem Pharmacol; 2004 Aug 01; 68(3):493-502. PubMed ID: 15242815
    [Abstract] [Full Text] [Related]

  • 6. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
    Verschraagen M, Kedde MA, Hausheer FH, Van Der Vijgh WJ.
    Cancer Chemother Pharmacol; 2003 Jun 01; 51(6):499-504. PubMed ID: 12715205
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
    Masuda N, Negoro S, Hausheer F, Nakagawa K, Matsui K, Kudoh S, Takeda K, Yamamoto N, Yoshimura N, Ohashi Y, Fukuoka M.
    Cancer Chemother Pharmacol; 2011 Mar 01; 67(3):533-42. PubMed ID: 20473611
    [Abstract] [Full Text] [Related]

  • 8. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.
    Clin Cancer Res; 2004 May 15; 10(10):3386-95. PubMed ID: 15161693
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
    Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ.
    Br J Cancer; 2004 Apr 19; 90(8):1654-9. PubMed ID: 15083199
    [Abstract] [Full Text] [Related]

  • 10. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
    Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR.
    Cancer Chemother Pharmacol; 2010 Apr 19; 65(5):941-51. PubMed ID: 19714332
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.
    Cancer Chemother Pharmacol; 2002 Mar 01; 49(3):201-10. PubMed ID: 11935212
    [Abstract] [Full Text] [Related]

  • 13. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ.
    Eur J Cancer; 2002 May 01; 38(8):1148-56. PubMed ID: 12008205
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):367-74. PubMed ID: 11976830
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB.
    Cancer Chemother Pharmacol; 2009 Jul 01; 64(2):233-41. PubMed ID: 19011858
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS, Kanekal S, Lin XR, Leung TW, Chan AT, Yeo W, Yu S, Chak K, Leavitt R, Johnson P.
    Cancer; 2001 Jun 15; 91(12):2369-77. PubMed ID: 11413527
    [Abstract] [Full Text] [Related]

  • 18. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G.
    Laryngoscope; 2004 Sep 15; 114(9):1660-7. PubMed ID: 15475801
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
    Verschraagen M, Zwiers TH, Torun E, Donker MG, Reinhoud NJ, Van der Vijgh WJ.
    J Pharm Sci; 2003 May 15; 92(5):1040-50. PubMed ID: 12712424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.